-
-
Call more information
660-596-2224 -
By blocking muscarinic receptors, some drugs already on the market could be used to prevent, or even reverse, the process of nerve degeneration common in axonopathic diseases, including diabetes. Interview with Paul Fernyhough, PhD For years, the conventional wisdom was to treat patients with diabetic peripheral neuropathy but there was no possibility of a cure. […]
Read MoreA new report published by the Centers for Disease Control and Prevention (CDC) reports preventable deaths due to opioids are far higher in rural counties compared to urban counties, and now significantly outweigh the overall national death rate. Interview with Mark Faul, PhD, MA Excess death rates from unintentional opioid overdose remain considerably higher in […]
Read MoreAccording to a new report, most criticisms of the CDC’s guidelines for opioid management of chronic noncancer pain did not include disclosures of any potential conflicts of interests with opioid manufacturers. Interviews with Caleb Alexander, MD, and Daniel B. Carr, MD In March of last year, the Centers for Disease Control and Prevention (CDC) released […]
Read MoreAuthors: Derek R. Laver, Ph.D. et al Anesthesiology 3 2017, Vol.126, 495-506. Background: Halogenated anesthetics activate cardiac ryanodine receptor 2–mediated sarcoplasmic reticulum Ca2+ release, leading to sarcoplasmic reticulum Ca2+ depletion, reduced cardiac function, and providing cell protection against ischemia-reperfusion injury. Anesthetic activation of ryanodine receptor 2 is poorly defined, leaving aspects of the protective mechanism uncertain. Methods: Ryanodine receptor 2 […]
Read MoreThe lack of pain specialists in many parts of the US has almost reached a crisis point, making the question of when and why to refer a patient especially timely. The recent Centers for Disease Control and Prevention (CDC) guidelines for opioid management suggest that clinicans should increase the frequency of follow-up visits when prescribing […]
Read More